Third Harmonic Bio, Inc. (THRD)

$10.215

+0.79

(+8.32%)▲

Market is closed - opens 8 PM, 07 Dec 2023

Insights on Third Harmonic Bio, Inc.

  • Vs SGEN

    In the last 1 year, Seagen, Inc. has given 83.0% return, outperforming this stock by 139.3%

Performance

  • $9.49
    $10.39
    $10.22
    downward going graph

    7.14%

    Downside

    Day's Volatility :8.66%

    Upside

    1.64%

    downward going graph
  • $3.75
    $23.43
    $10.22
    downward going graph

    63.31%

    Downside

    52 Weeks Volatility :83.99%

    Upside

    56.38%

    downward going graph

Returns

PeriodThird Harmonic Bio, Inc.Index (Russel 2000)
3 Months
56.91%
0.0%
6 Months
87.48%
0.0%
1 Year
-56.26%
-2.4%
3 Years
-52.08%
-6.5%

Highlights

Market Capitalization
373.0M
Book Value
$6.87
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
0.76
PE Ratio
12.16
Wall Street Target Price
5.3
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-10.03%
Return On Equity TTM
-12.42%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-37.7M
Diluted Eps TTM
0.76
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.11
EPS Estimate Next Year
-1.38
EPS Estimate Current Quarter
-0.27
EPS Estimate Next Quarter
-0.29

Analyst Recommendation

Buy
    70%Buy
    30%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Third Harmonic Bio, Inc.(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Downside of 48.12%

Current $10.22
Target $5.30

Technicals Summary

Sell

Neutral

Buy

Third Harmonic Bio, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Third Harmonic Bio, Inc.
Third Harmonic Bio, Inc.
46.88%
87.48%
-56.26%
-52.08%
-52.08%
Moderna, Inc.
Moderna, Inc.
8.62%
-38.31%
-54.89%
-50.93%
320.86%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-1.38%
9.73%
9.82%
65.7%
115.07%
Novo Nordisk A/s
Novo Nordisk A/s
-1.43%
23.95%
58.41%
192.13%
336.59%
Seagen, Inc.
Seagen, Inc.
0.74%
10.42%
83.05%
20.41%
247.89%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-8.19%
7.19%
13.58%
55.97%
97.18%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Third Harmonic Bio, Inc.
Third Harmonic Bio, Inc.
12.16
12.16
NA
-1.11
-0.12
-0.1
0.0
6.87
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.72
-0.22
-0.07
0.0
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
23.18
23.18
1.75
42.5
0.17
0.09
0.01
234.47
Novo Nordisk A/s
Novo Nordisk A/s
41.18
41.18
4.02
2.67
0.89
0.22
0.01
20.77
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-4.16
-0.28
-0.13
0.03
13.52
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.38
26.38
0.5
15.04
0.23
0.14
0.0
64.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Third Harmonic Bio, Inc.
Third Harmonic Bio, Inc.
Buy
$373.0M
-52.08%
12.16
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$30.4B
320.86%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$88.5B
115.07%
23.18
30.47%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$459.0B
336.59%
41.18
35.11%
Seagen, Inc.
Seagen, Inc.
Hold
$40.2B
247.89%
NA
-32.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.5B
97.18%
26.38
35.94%

Institutional Holdings

  • Orbimed Advisors, LLC

    14.32%

  • Bvf Inc

    10.82%

  • EcoR1 Capital, LLC

    7.39%

  • General Atlantic Llc

    7.33%

  • TANG CAPITAL MANAGEMENT LLC

    4.46%

  • COMMODORE CAPITAL LP

    4.21%

Company Information

third harmonic bio is a clinical-stage company developing a highly selective, oral kit inhibitor for treatment of severe allergy and inflammation. kit is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the key mediator of the inflammation associated with allergic diseases. our lead product candidate, thb001, is the first highly selective, oral small-molecule kit inhibitor to enter clinical development. with promising drug-like properties and an encouraging early clinical profile, thb001 has the potential to revolutionize the treatment of a broad range of dermatologic, respiratory, and gastrointestinal allergic and mast-cell mediated inflammatory diseases.

Organization
Third Harmonic Bio, Inc.
Employees
32
CEO
Ms. Natalie C. Holles
Industry
Healthcare

Discover More

FAQs